Why the study?
Does a standardized transition protocol improve the achievement of therapeutic INR values in adult patients transitioning from bivalirudin to warfarin?
Does a standardized transition protocol improve the achievement of therapeutic INR values in adult patients transitioning from bivalirudin to warfarin?
Implementation of a standardized bivalirudin-warfarin transition protocol significantly improves the achievement of therapeutic INR values upon bivalirudin discontinuation.
Answers are grounded in this paper and cite their sources.
May support standardized bivalirudin-warfarin transition protocols; leaves open need for randomized confirmation before practice change.
BACKGROUND: Transition from bivalirudin to long-term warfarin therapy is often difficult to execute due to bivalirudin prolongation of the international normalized ratio (INR), and literature to help guide this transition is extremely limited. OBJECTIVE: To assess the transition from bivalirudin to warfarin after implementation of an institution-wide transition protocol. METHODS: In this retrospective quasiexperimental study, adult patients receiving bivalirudin directly followed by warfarin for nonprocedural systemic anticoagulation were evaluated to determine the frequency of successful transition to warfarin. Participants were compared before (preprotocol) and after (postprotocol) the implementation of the transition protocol. RESULTS: A total of 39 patients met inclusion criteria and were included in the analysis (preprotocol = 19; postprotocol = 20). The percentage of patients achieving a successful transition was significantly higher in the postprotocol group compared with the preprotocol group (80.0% vs 42.1%, P = 0.015). Bleeding events were similar between the 2 groups (23.1% vs 16.7%, P = 0.689). Withholding of warfarin doses or the use of anticoagulant reversal agents or blood transfusions for supratherapeutic INR levels, surgical procedures, or drop in hemoglobin was numerically lower in the postprotocol group compared with the preprotocol group (16.7% vs 46.2%, P = 0.202). CONCLUSION: Implementation of a simplistic bivalirudin-warfarin transition protocol significantly increased the frequency of therapeutic INR results on bivalirudin discontinuation. Additionally, patients treated according to this protocol were less likely to have warfarin doses withheld or require reversal agents. Larger studies testing this transition strategy are warranted.
No takes yet. Share an insight, caveat, or question.
Rollins et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: